Several cannabis companies released updates in early March, highlighting the pressures currently shaping the industry. Some operators are increasing their involvement in policy discussions, while others are reporting stronger operational performance through earnings results or addressing capital structure challenges.
High Tide, Cresco Labs, The Cannabist Company, and WM Technology illustrate three key themes influencing the sector today: policy engagement, improving financial performance, and ongoing debt negotiations.
Policy Push: High Tide and NuLeaf Naturals Join U.S. Medical Cannabis Council
High Tide Inc. and its U.S. hemp-derived CBD subsidiary NuLeaf Naturals joined the National Compassionate Care Council (NCCC) as founding members. The council brings together organizations across the medicinal cannabis sector to improve patient access to cannabinoid therapies and promote evidence-based policy development.
The NCCC works to modernize healthcare standards for cannabinoid products and encourages regulatory frameworks that prioritize product quality, scientific research, and patient outcomes. Other founding members include Tilray, Medterra CBD, Lazarus Naturals, Feals, and Realm of Caring.
High Tide joined the council as part of its expanding presence in the U.S. cannabinoid wellness market through brands such as NuLeaf Naturals and FAB CBD. NuLeaf Naturals manufactures cannabinoid products in a cGMP-certified facility and distributes them through its website and select retail stores across the United States.
High Tide operates across several segments of the cannabis industry. Through its Canna Cabana brand, the company runs one of Canada’s largest cannabis retail networks, with more than 200 stores. It also maintains international exposure through Remexian Pharma, a German pharmaceutical distributor specializing in medical cannabis imports.
Developments in Washington continue to influence companies operating in hemp-derived cannabinoid markets. Federal discussions around cannabis rescheduling and the possibility of Medicare reimbursement for certain cannabinoid therapies could reshape how healthcare systems regulate and reimburse cannabinoid-based wellness products.
By joining initiatives such as the NCCC, cannabis companies increasingly participate in regulatory discussions as the industry moves closer to potential federal reforms in the United States.
Earnings Strength: Cresco Labs Reports Revenue Growth and Margin Expansion
Cresco Labs reported financial results for the fourth quarter and full year ending December 31, 2025, highlighting improvements in profitability metrics and operating cash flow.
Fourth-quarter revenue reached $162 million, while full-year revenue totaled $656 million. The company reported operating cash flow of $27 million for the quarter and $73 million for the full year, with free cash flow reaching $38 million in 2025.
Gross profit for the fourth quarter totaled $83 million, with adjusted gross margin reaching 52.2%. Adjusted EBITDA for the quarter reached $40 million, representing a margin of 25%.
For the full year, Cresco Labs reported adjusted EBITDA of $157 million and an adjusted EBITDA margin of 24%.
Despite these operational improvements, the company recorded a net loss of $89 million in the fourth quarter and $140 million for the year. These figures included non-cash impairment charges related to valuation adjustments tied to its New York reporting unit and asset valuation changes associated with the sale of Sonoma’s Finest in California.
Industry consolidation remains a defining trend in the U.S. cannabis market. Operators with stronger balance sheets and consistent cash flow may be better positioned to expand through acquisitions or organic growth as weaker competitors exit the market. As of the end of 2025, Cresco Labs reported $91 million in cash and cash equivalents and total current assets of $259 million.
Debt Talks: The Cannabist Company Extends Forbearance Agreement
The Cannabist Company announced that holders of two series of senior secured notes extended their forbearance agreement with the company until March 17, 2026.
The agreement covers the company’s 9.25% Senior Secured Notes and 9.00% Senior Secured Convertible Notes, both scheduled to mature in December 2028.
Under the extension, noteholders will continue refraining from exercising their rights or remedies under the governing indenture while negotiations continue. Companies and creditors typically use forbearance agreements to gain additional time to explore restructuring options or amend existing debt terms. The extension appears unrelated to a recent Canadian court ruling involving former Columbia Care CEO Nicholas Vita, which concerned a personal loan guarantee tied to shares pledged in a margin account rather than corporate debt obligations.
The Cannabist Company, formerly known as Columbia Care, operates a multi-state cannabis platform with licenses in 11 U.S. jurisdictions.
The company runs 69 facilities, including 54 dispensaries and 15 cultivation and manufacturing sites, with additional facilities under development.
Across the cannabis industry, multi-state operators are increasingly pursuing debt negotiations and refinancings as they navigate limited access to traditional financing channels.
What These Developments Indicate for the Cannabis Sector
The latest announcements reflect a cannabis industry moving through several simultaneous transitions. These developments illustrate how operators are balancing growth ambitions with financial discipline in a challenging market environment.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
